哈药股份：全资子公司签订《技术转让（委托）合同》

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (600664) announced a contract for technology transfer with Shanghai Bozhi Research Co., Ltd. to purchase the clinical approval for Dapoxetine tablets, indicating a strategic move to enhance its product pipeline and market presence [1] Group 1 - The total amount of the contract is expected to be 44.8 million yuan, funded by Harbin Pharmaceutical's own resources [1] - The transaction does not constitute a related party transaction or a major asset restructuring, thus does not require approval from the shareholders' meeting [1]